熱門資訊> 正文

CRISPR与Sirius Therapeutics合作开发Sirius疗法

2025-05-20 21:50

CRISPR Therapeutics (NASDAQ:CRSP) and Sirius Therapeutics have formed a partnership to jointly develop and commercialize small interfering RNA (siRNA) therapies.
The collaboration will initially focus on co-developing SRSD107, a siRNA therapy targeting factor XI for the treatment of thromboembolic disorders.
As part of the agreement, CRISPR Therapeutics will pay Sirius $25M in cash and invest $70M in equity.
CRISPR said it will also have the option to exclusively license up to two additional siRNA programs from Sirius in the future.

More on CRISPR Therapeutics

Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines
CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)
Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course
Baby is given world's first personalized CRISPR therapy
SA analyst downgrades: VTRS, MRVL, MAR, NTR, CRSP, DB, VRSK, OCSL

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。